Alan T McGown
Overview
Explore the profile of Alan T McGown including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bisby R, Botchway S, Hadfield J, McGown A, Parker A, Scherer K
Eur J Cancer
. 2012 Jan;
48(12):1896-903.
PMID: 22209092
To investigate within live mammalian cells the uptake and disposition of combretastatins, fluorescence lifetime imaging was used with two-photon excitation (2PE). Combretastatin A4 (CA4) and analogues are potential anticancer drugs...
2.
Flower K, Khalifa I, Bassan P, Demoulin D, Jackson E, Lockyer N, et al.
Analyst
. 2010 Nov;
136(3):498-507.
PMID: 21088767
Recently a new di-gold(I) organometallic complex [1,3-(Ph(3)PAu)(2)-C(6)H(4)] (KF0101) has been synthesised and found to exhibit cytotoxic activity in vitro. Subsequently it has been demonstrated that KF0101 shows little or no...
3.
Ducki S, Rennison D, Woo M, Kendall A, Chabert J, McGown A, et al.
Bioorg Med Chem
. 2009 Oct;
17(22):7698-710.
PMID: 19837593
The alpha-methyl chalcone SD400 is a potent inhibitor of tubulin assembly and possesses potent anticancer activity. Various chalcone analogues were synthesized and evaluated for their cell growth inhibitory properties against...
4.
Flower K, Pritchard R, McGown A
Angew Chem Int Ed Engl
. 2006 Nov;
45(45):7489.
PMID: 17103479
No abstract available.
5.
Flower K, Pritchard R, McGown A
Angew Chem Int Ed Engl
. 2006 Aug;
45(39):6535-7.
PMID: 16917797
No abstract available.
6.
Hasan J, Shnyder S, Clamp A, McGown A, Bicknell R, Presta M, et al.
Clin Cancer Res
. 2005 Nov;
11(22):8172-9.
PMID: 16299249
Background: In previous experiments, we showed that heparin oligosaccharides inhibit the angiogenic cytokine fibroblast growth factor-2. Here, we present the first in vivo study of size-fractionated heparin oligosaccharides in four...
7.
Bruce I, Slevin N, Homer J, McGown A, Ward T
Anticancer Drugs
. 2005 Jul;
16(7):719-26.
PMID: 16027519
The tyrosine kinase inhibitor imatinib (STI 571; glivec) is a potent inhibitor of bcr-abl, c-kit and platelet-derived growth factor receptors. Imatinib was evaluated both alone and in combination with established...
8.
Hadfield J, Gaukroger K, Hirst N, Weston A, Lawrence N, McGown A
Eur J Med Chem
. 2005 Jun;
40(6):529-41.
PMID: 15922837
A series of combretastatins substituted with epoxides, amides and small alkyl groups has been synthesised and evaluated for cytotoxicity and their ability to inhibit the assembly of tubulin. The methyl...
9.
Lawrence N, McGown A
Curr Pharm Des
. 2005 May;
11(13):1679-93.
PMID: 15892668
The development of combretastatin as an antimitotic agent has led to an enormous effort to design other tubulin-targeting agents. The intriguing discovery that combretastatin A-4 phosphate causes selective damage to...
10.
Ward T, Danson S, McGown A, Ranson M, Coe N, Jayson G, et al.
Clin Cancer Res
. 2005 Apr;
11(7):2695-701.
PMID: 15814651
Purpose: The purpose of our study was to investigate the cellular accumulation, DNA cross-linking ability, and cellular toxicity of RH1 (2,5-diaziridinyl-3-[hydroxymethyl[-6-methyl-1,4-benzoquinone), a novel DNA alkylating agent currently in clinical trials....